bristol myers squibb biontech - Search News

News

BioNTech, Bristol Myers Squibb and cancer immunotherapy

Seeking Alpha · 1d

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I like BMY more than BNTX.

The Wall Street Journal on MSN · 4d

BioNTech Sets Cancer-Drug Deal With Bristol Myers Squibb

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in a deal potentially worth more than $11 billion to the German drugmaker.

Reuters on MSN · 4d

Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapy

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's next-generation cancer immunotherapy, which could take on rival Merck & Co's best-selling drug Keytruda.

Medical Dialogues1d

Bristol Myers Squibb, BioNTech ink pact to co-develop, co-commercialize investigational bispecific antibody for multiple solid tumor types

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

3d

Bristol Myers Collaborates With BNTX for Oncology Candidate

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...

4d

BioNTech-Aktie steigt - Bristol zahlt bis zu $11,1 Mrd. in Krebsmedikament-Deal

Bristol-Myers Squibb wird BioNTech bis zu 11,1 Milliarden Dollar (9,7 Milliarden Euro) für die Lizenzierung eines ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results